Controlled Therapeutics receives grant from Scottish government
This article was originally published in Scrip
Executive Summary
Controlled Therapeutics (Scotland) has received a £930,000 grant from the Scottish Executive's regional selective assistance programme, which will go towards creating 23 new positions at its East Kilbride facility. The company, a subsidiary of the US firm Cytokine PharmaSciences, conducts research and manufacturing there, and Cytokine Pharmasciences' president and CEO Dennis Wilson said the company was investing $6 million in Scotland. Patent protection on its Hydrogel technology, which was acquired from the University of Strathclyde, runs out in 2012, but it plans to develop both its existing polymer technology and new technologies based on linear polymers.
You may also be interested in...
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.
Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study
Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.